Identifying responders to melphalan and dexamethasone for newly diagnosed multiple myeloma patients
Background: MY7 clinical trial compared dexamethasone plus melphalan (MD) vs. prednisone plus melphalan (MP) in multiple myeloma treatment and found no statistically significant difference in overall survival (OS) between the two groups. But, patients reacted to treatment differently. We aimed to id...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en en |
| Published: |
2008
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1974/1330 |